Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Feb 20, 2024 2:37pm
167 Views
Post# 35889410

RE:Next leg of the uptick from recent low

RE:Next leg of the uptick from recent low
Hey CF, not like you to suggest the company is in disaster recovery mode,
Also you are wrong on "yet another trial with Roche" as it is a continuation and expansion of the trial that they already had with Roche suppliing the CI, also as you state we are not going to get a q2 update but it will be a q4 and year end update that should be announced sometime most likely this week or next as this does not affect the blackout. Also CF you have still not retracted your statement that Matt Coffey exercised 350k options which was very misleading to a lot of people.
My take and with the thought that they may to only enrol as few as 20 patients to get the efficacy signal seems to suggest that the ANAL ( scaa) trial may now be the fastest route to approval.
I am still hopeful for a BO but my thoughts are that we will most likely partner at this point and still thinking that BP might be holding out for OS on either mbc or panc or both before making a move but thinking that they are hoping to have something in place by the AGM.
<< Previous
Bullboard Posts
Next >>